Starting at the Front Line in Metastatic Pancreatic Cancer As New Options Emerge, How Do You Select and Sequence?
Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.
Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma
Experts in multiple myeloma discussed optimal dosing strategies for bispecific antibodies for patients with relapsed/refractory multiple myeloma.
Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer
Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.
Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care
Carl He, MD, explores the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care.
Reconsidering REMS Mandate May Improve CAR T-Cell Therapy Accessibility
Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.
2024 Statistics May Impact Next Decade of Cancer Treatment
Julie M. Vose, MD, MBA, reviews the rising cancer diagnoses that are estimated to impact 2 million people in 2024.
